Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agathe Bajard

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Oncology|July 8, 2011
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancerThomas Bachelot, Agathe Bajard, Isabelle Ray-Coquard, et al.
Breast Cancer Research : BCR|October 22, 2008
A candidate molecular signature associated with tamoxifen failure in primary breast cancerJulie A Vendrell, Katherine E Robertson, Patrice Ravel, et al.
Bulletin Du Cancer|September 20, 2011
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective studyIrène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, et al.
Cancer Research|June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancerSana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
Orphanet Journal of Rare Diseases|March 28, 2013
Experimental designs for small randomised clinical trials: an algorithm for choiceCatherine Cornu, Behrouz Kassai, Roland Fisch, et al.
Cancer Research|July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progressionVanja Sisirak, Julien Faget, Michael Gobert, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Oncology|July 8, 2011
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancerThomas Bachelot, Agathe Bajard, Isabelle Ray-Coquard, et al.
Breast Cancer Research : BCR|October 22, 2008
A candidate molecular signature associated with tamoxifen failure in primary breast cancerJulie A Vendrell, Katherine E Robertson, Patrice Ravel, et al.
Bulletin Du Cancer|September 20, 2011
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective studyIrène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, et al.
Cancer Research|June 24, 2011
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancerSana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.
Orphanet Journal of Rare Diseases|March 28, 2013
Experimental designs for small randomised clinical trials: an algorithm for choiceCatherine Cornu, Behrouz Kassai, Roland Fisch, et al.
Cancer Research|July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progressionVanja Sisirak, Julien Faget, Michael Gobert, et al.
Pageof 2